Quantum-Si’s New Preprint Showcases Advances in Protein Variant Detection using ProteoVue™ Software with Next-Generation Protein Sequencing™
Quantum-Si (QSI) announced a new preprint demonstrating its proprietary bioinformatics tool ProteoVue, designed for detecting and quantifying Single Amino Acid Variants (SAAVs). The tool is part of the Platinum Analysis Software for the company's Platinum benchtop instrument. ProteoVue enables detection of protein variations, quantification of post-translational modifications, and characterization of proteins with unnatural amino acids.
The software leverages advanced signal processing, neural network-driven kinetic signature modeling, and clustering framework to provide insights into protein variants, including those undetectable by mass spectrometry. This development aligns with QSI's recent collaboration with NVIDIA to enhance sequencing performance through AI and follows the announcement of their next-generation platform, Proteus.
Quantum-Si (QSI) ha annunciato un nuovo preprint che dimostra il proprio strumento di bioinformatica ProteoVue, progettato per rilevare e quantificare le Variazioni di Singolo Aminoacido (SAAV). Questo strumento è parte del Software di Analisi Platinum per l'unità da banco Platinum dell'azienda. ProteoVue consente la rilevazione di variazioni proteiche, la quantificazione di modifiche post-traduzionali e la caratterizzazione di proteine con aminoacidi non naturali.
Il software sfrutta l'elaborazione avanzata dei segnali, la modellazione delle firme cinetiche guidata da reti neurali e un quadro di clustering per fornire approfondimenti sulle varianti proteiche, comprese quelle non rilevabili tramite spettrometria di massa. Questo sviluppo è in linea con la recente collaborazione di QSI con NVIDIA per migliorare le prestazioni di sequenziamento attraverso l'IA e segue l'annuncio della loro piattaforma di nuova generazione, Proteus.
Quantum-Si (QSI) anunció un nuevo preprint que demuestra su herramienta de bioinformática patentada ProteoVue, diseñada para detectar y cuantificar Variantes de Aminoácidos Sencillos (SAAV). La herramienta forma parte del Software de Análisis Platinum para el instrumento de mesa Platinum de la empresa. ProteoVue permite detectar variaciones proteicas, cuantificar modificaciones post-traduccionales y caracterizar proteínas con aminoácidos no naturales.
El software utiliza procesamiento avanzado de señales, modelado de firma cinética impulsado por redes neuronales, y un marco de agrupamiento para proporcionar información sobre variantes proteicas, incluidas aquellas no detectables mediante espectrometría de masas. Este desarrollo se alinea con la reciente colaboración de QSI con NVIDIA para mejorar el rendimiento de secuenciación a través de IA y sigue al anuncio de su plataforma de próxima generación, Proteus.
Quantum-Si (QSI)는 단일 아미노산 변이(SAAV)의 검출 및 정량화를 위해 설계된 고유의 생물정보학 도구 ProteoVue를 Demonstrating하는 새로운 프리프린트를 발표했습니다. 이 도구는 회사의 Platinum 벤치탑 장비를 위한 Platinum 분석 소프트웨어의 일부입니다. ProteoVue는 단백질 변이의 검출, 번역 후 수정의 정량화 및 비자연 아미노산을 가진 단백질의 특성화를 가능하게 합니다.
이 소프트웨어는 고급 신호 처리, 신경망 기반의 동적 서명 모델링 및 클러스터링 프레임워크를 활용하여 질량 분석법으로는 검출할 수 없는 변이 단백질에 대한 통찰력을 제공합니다. 이 개발은 QSI가 AI를 통한 염기서열 성능 향상을 위해 NVIDIA와 최근에 협력했음을 반영하며, 차세대 플랫폼인 Proteus 발표에 이어 진행된 것입니다.
Quantum-Si (QSI) a annoncé un nouveau préprint démontrant son outil bioinformatique breveté ProteoVue, conçu pour détecter et quantifier les Variantes de Single Amino Acid (SAAVs). Cet outil fait partie du logiciel d'analyse Platinum pour l'instrument de paillasse Platinum de l'entreprise. ProteoVue permet la détection des variations protéiques, la quantification des modifications post-traductionnelles et la caractérisation des protéines avec des acides aminés non naturels.
Le logiciel exploite un traitement avancé des signaux, un modélisation de signature cinétique pilotée par des réseaux neuronaux et un cadre de regroupement pour fournir des informations sur les variants protéiques, y compris ceux indétectables par spectrométrie de masse. Ce développement s'inscrit dans la récente collaboration de QSI avec NVIDIA pour améliorer les performances de séquençage grâce à l'IA et suit l'annonce de leur plateforme de nouvelle génération, Proteus.
Quantum-Si (QSI) hat einen neuen Preprint angekündigt, der sein hauseigenes bioinformatisches Werkzeug ProteoVue demonstriert, das zur Erkennung und Quantifizierung von Einzelaminosäurevarianten (SAAVs) entwickelt wurde. Das Werkzeug ist Teil der Platinum-Analyse-Software für das Platinum-Benchtop-Gerät des Unternehmens. ProteoVue ermöglicht die Erkennung von Proteinvariationen, die Quantifizierung posttranslationaler Modifikationen und die Charakterisierung von Proteinen mit unnatürlichen Aminosäuren.
Die Software nutzt fortschrittliche Signalverarbeitung, modellierungsbasierte kinetische Signaturanalysen durch neuronale Netze und ein Cluster-Framework, um Einblicke in Proteinvarianten zu geben, einschließlich derjenigen, die durch Massenspektrometrie nicht nachweisbar sind. Diese Entwicklung steht im Einklang mit QSI's kürzlicher Zusammenarbeit mit NVIDIA zur Verbesserung der Sequenzierungsleistung durch KI und folgt der Ankündigung ihrer nächsten Plattform, Proteus.
- Development of advanced bioinformatics tool ProteoVue for protein analysis
- Strategic collaboration with NVIDIA for AI-enhanced sequencing capabilities
- Early access program launch for ProteoVue workflow
- None.
Insights
Quantum-Si's new ProteoVue software represents a significant technological advancement in protein analysis. The platform's ability to detect Single Amino Acid Variants (SAAVs) at the single-molecule level surpasses traditional mass spectrometry limitations. This capability is particularly valuable for biomarker discovery and protein therapeutic development.
The integration with NVIDIA for AI-powered data processing indicates a strategic move to handle large-scale protein sequencing data, especially with their upcoming Proteus platform. The real-time measurement of individual protein molecules and differentiation between variant types positions QSI at the forefront of next-generation protein sequencing technology.
However, while technologically impressive, the commercial impact remains uncertain. The early access program suggests the software is still in development phase and market adoption will depend on validation from research institutions and pharmaceutical companies. The
The collaboration with NVIDIA marks a important technical milestone. Implementing neural network-driven kinetic signature modeling for protein analysis requires significant computational power and sophisticated AI algorithms. This partnership could accelerate data processing capabilities and improve accuracy in variant detection.
The integration of advanced signal processing with AI-driven analysis creates a powerful bioinformatics pipeline. This combination is essential for processing the massive datasets generated by single-molecule sequencing. However, success will depend on effective optimization of these AI models for protein-specific applications and seamless integration with existing laboratory workflows.
Announces early access availability of ProteoVue Software
ProteoVue is part of broader set of innovation initiatives, including the Company’s recently announced collaboration with NVIDIA, to leverage AI to enhance sequencing performance
ProteoVue is an advanced analysis workflow within the Platinum Analysis Software, designed to detect and quantify amino acid variants in complex protein systems. ProteoVue’s capabilities enable detecting a broad variety of protein variation including isobaric variations, quantifying post-translational modifications, and characterizing proteins with unnatural amino acids. ProteoVue empowers cutting-edge research in proteoform science and protein therapeutics.
“ProteoVue is a major step forward in harnessing the power of Next-Generation Protein Sequencing,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “This innovation showcases how our NGPS™ platform enables precise and scalable proteomic analysis, providing researchers with tools to better uncover protein variations critical for understanding biology and disease.”
The paper establishes ProteoVue as a comprehensive tool for SAAV detection and quantification. Using Quantum-Si’s NGPS technology, ProteoVue leverages advanced signal processing, neural network-driven kinetic signature modeling, and a robust clustering framework to provide unparalleled insights into protein variants, including those traditionally undetectable by mass spectrometry.
Key Findings:
- Single Molecule Variant Detection: ProteoVue demonstrates the ability to detect and quantify amino acid variants through real-time measurement of individual protein molecules.
- Detection Across Variant Types: The pipeline differentiates between different variant types by measuring change in single molecule kinetic features associated with a variant.
“This paper underscores the potential of ProteoVue to support advanced research in biomarker discovery, precision medicine, and proteomics” said John Vieceli, Chief Product Officer at Quantum-Si. “The work described here is part of our broader effort to continually enhance NGPS analysis pipelines for customers. Our proprietary analysis tools, combined with our collaboration with NVIDIA, will enable us to further leverage AI and GPUs to process the large volume of data expected to be produced across our instrument portfolio, including the recently announced next generation platform, Proteus.”
The Company previously announced a collaboration relationship with NVIDIA as part of its Investor & Analyst Day on November 20, 2024 which introduced the Proteus platform and other advancements.
Quantum-Si invites researchers and potential collaborators to early access of the ProteoVue workflow. To learn how you can become part of the journey toward deeper understanding and groundbreaking discoveries, visit: Protein Variant Applications.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241220584164/en/
Investor
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com
Media
Katherine Atkinson
SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What capabilities does Quantum-Si's ProteoVue software offer for protein analysis?
How does QSI's collaboration with NVIDIA enhance their protein sequencing technology?
What are the key features of QSI's ProteoVue for Single Amino Acid Variants detection?
How can researchers access Quantum-Si's ProteoVue software?
